MX2020006285A - Vacunas contra el cancer dirigidas a survivina y sus usos. - Google Patents
Vacunas contra el cancer dirigidas a survivina y sus usos.Info
- Publication number
- MX2020006285A MX2020006285A MX2020006285A MX2020006285A MX2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A MX 2020006285 A MX2020006285 A MX 2020006285A
- Authority
- MX
- Mexico
- Prior art keywords
- survivin
- disclosed
- cancer vaccines
- nucleic acid
- vaccines targeting
- Prior art date
Links
- 102000000763 Survivin Human genes 0.000 title abstract 6
- 108010002687 Survivin Proteins 0.000 title abstract 6
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598267P | 2017-12-13 | 2017-12-13 | |
| PCT/US2018/065529 WO2019118766A2 (en) | 2017-12-13 | 2018-12-13 | Cancer vaccines targeting survivin and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006285A true MX2020006285A (es) | 2020-09-17 |
Family
ID=66734396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006285A MX2020006285A (es) | 2017-12-13 | 2018-12-13 | Vacunas contra el cancer dirigidas a survivina y sus usos. |
| MX2025004799A MX2025004799A (es) | 2017-12-13 | 2020-07-13 | Vacunas contra el cancer dirigidas a survivina y sus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004799A MX2025004799A (es) | 2017-12-13 | 2020-07-13 | Vacunas contra el cancer dirigidas a survivina y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12064473B2 (enExample) |
| EP (1) | EP3723793A4 (enExample) |
| JP (3) | JP7385569B2 (enExample) |
| KR (2) | KR102648079B1 (enExample) |
| CN (1) | CN111479583A (enExample) |
| AU (2) | AU2018383664B2 (enExample) |
| BR (1) | BR112020011820A2 (enExample) |
| CA (1) | CA3083534A1 (enExample) |
| MX (2) | MX2020006285A (enExample) |
| RU (1) | RU2751253C1 (enExample) |
| WO (1) | WO2019118766A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020011820A2 (pt) * | 2017-12-13 | 2020-11-17 | Inovio Pharmaceuticals, Inc. | moléculas de ácido nucleico e seus usos, vetor, composições, proteínas e vacinas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| AU2013243954A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| CN106456735B (zh) | 2014-03-28 | 2021-06-29 | 华盛顿大学商业中心 | 乳腺癌和卵巢癌疫苗 |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2016179573A1 (en) * | 2015-05-07 | 2016-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Variant survivin vaccine for treatment of cancer |
| TW201723171A (zh) * | 2015-09-15 | 2017-07-01 | 艾法西斯公司 | 基於李斯特菌屬之免疫原性組成物及其於癌症預防與治療中之使用方法 |
| BR112020011820A2 (pt) * | 2017-12-13 | 2020-11-17 | Inovio Pharmaceuticals, Inc. | moléculas de ácido nucleico e seus usos, vetor, composições, proteínas e vacinas |
-
2018
- 2018-12-13 BR BR112020011820-6A patent/BR112020011820A2/pt unknown
- 2018-12-13 US US16/219,520 patent/US12064473B2/en active Active
- 2018-12-13 JP JP2020532715A patent/JP7385569B2/ja active Active
- 2018-12-13 AU AU2018383664A patent/AU2018383664B2/en active Active
- 2018-12-13 RU RU2020122872A patent/RU2751253C1/ru active
- 2018-12-13 KR KR1020207019758A patent/KR102648079B1/ko active Active
- 2018-12-13 EP EP18889469.5A patent/EP3723793A4/en active Pending
- 2018-12-13 CA CA3083534A patent/CA3083534A1/en active Pending
- 2018-12-13 WO PCT/US2018/065529 patent/WO2019118766A2/en not_active Ceased
- 2018-12-13 CN CN201880080439.6A patent/CN111479583A/zh active Pending
- 2018-12-13 KR KR1020247008261A patent/KR20240038139A/ko active Pending
- 2018-12-13 MX MX2020006285A patent/MX2020006285A/es unknown
-
2020
- 2020-07-13 MX MX2025004799A patent/MX2025004799A/es unknown
-
2023
- 2023-08-01 JP JP2023125566A patent/JP7659599B2/ja active Active
-
2024
- 2024-07-08 US US18/765,553 patent/US20240358809A1/en active Pending
- 2024-11-18 AU AU2024264712A patent/AU2024264712A1/en active Pending
-
2025
- 2025-03-28 JP JP2025056239A patent/JP2025092647A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021506265A (ja) | 2021-02-22 |
| CN111479583A (zh) | 2020-07-31 |
| KR102648079B1 (ko) | 2024-03-18 |
| US20190175707A1 (en) | 2019-06-13 |
| MX2025004799A (es) | 2025-05-02 |
| EP3723793A4 (en) | 2022-01-19 |
| US12064473B2 (en) | 2024-08-20 |
| JP7385569B2 (ja) | 2023-11-22 |
| EP3723793A2 (en) | 2020-10-21 |
| CA3083534A1 (en) | 2019-06-20 |
| KR20200096957A (ko) | 2020-08-14 |
| JP2025092647A (ja) | 2025-06-19 |
| AU2024264712A1 (en) | 2024-12-05 |
| AU2018383664A1 (en) | 2020-07-16 |
| US20240358809A1 (en) | 2024-10-31 |
| BR112020011820A2 (pt) | 2020-11-17 |
| WO2019118766A3 (en) | 2019-09-19 |
| AU2018383664B2 (en) | 2024-12-05 |
| KR20240038139A (ko) | 2024-03-22 |
| RU2021117812A3 (enExample) | 2021-11-08 |
| JP2023155245A (ja) | 2023-10-20 |
| RU2751253C1 (ru) | 2021-07-12 |
| WO2019118766A2 (en) | 2019-06-20 |
| JP7659599B2 (ja) | 2025-04-09 |
| RU2021117812A (ru) | 2021-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025009055A (es) | Vectores de neoantigeno de alfavirus | |
| IL268836A (en) | Bispecific molecules that bind CD137 and cancer antigens and their uses | |
| PH12019501959A1 (en) | Therapeutic rna | |
| CY1125385T1 (el) | Συστημα πολλαπλων φορεων και χρησεις αυτου | |
| CY1123697T1 (el) | Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη | |
| CY1123274T1 (el) | Αντισωματα εναντι-οχ40 και χρησεις αυτων | |
| CY1122035T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
| GB2557123A (en) | Modified cells and methods of therapy | |
| MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
| MX2018008051A (es) | Variantes de beta-glucanasa y polinucleotidos que las codifican. | |
| MD4733B1 (ro) | Anticorpi anti-TIGIT | |
| AU2013358947A8 (en) | WT1 vaccine | |
| SG10201908086SA (en) | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| MX2024014237A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| EP3998341A3 (en) | Adenoviral vectors | |
| MX2018009506A (es) | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. | |
| NZ752275A (en) | Compositions and methods for enhancing the stability of transgenes in poxviruses | |
| MX2020006216A (es) | Vacunas contra el cancer dirigidas a prame y sus usos. | |
| MX2018005872A (es) | Profarmacos de acido nucleico. |